Dozens of patents protect AbbVie’s pricey cancer drug against competition, report finds

(By Katie Adams for Becker’s Hospital Review)

AbbVie wields at least 88 patents to guard Imbruvica, its expensive cancer treatment, against competition from generic drugmakers, according to recent analysis from the nonprofit I-MAK.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org